631911-95-0

Basic information

• Product Name: 2-bromo-3-methyl-5-nitrobenzoic acid
• Synonyms: 2-bromo-3-methyl-5-nitrobenzoic acid
• CAS NO: 631911-95-0
• Molecular Formula: C₈H₆BrNO₄
• Molecular Weight: 260.04154
• Mol File: 631911-95-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 385.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.777±0.06 g/cm3(Predicted)
• PKA: 2.22±0.10(Predicted)
• CAS DataBase Reference: 2-bromo-3-methyl-5-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-3-methyl-5-nitrobenzoic acid(631911-95-0)
• EPA Substance Registry System: 2-bromo-3-methyl-5-nitrobenzoic acid(631911-95-0)

Safety Data

• Hazardous Substances Data: 631911-95-0(Hazardous Substances Data)

Upstream product

• 66176-17-8 6-methylisatoic anhydride 
• 4389-45-1 3-methylantranilic acid 
• 500028-91-1 8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione 
• 631911-94-9 2-amino-3-methyl-5-nitro-benzoic acid methyl ester 
• 53663-39-1 3-methyl-2-bromobenzoic acid 
• 179897-93-9 methyl 2-bromo-3-methyl-5-nitrobenzoate 

Downstream Products

• 179897-93-9 methyl 2-bromo-3-methyl-5-nitrobenzoate 
• 631911-96-1 (2-bromo-3-methyl-5-nitro-phenyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

Conjugated complement cascade inhibitors

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.